You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlurandrenolide
Accession NumberDB00846  (APRD00982)
TypeSmall Molecule
GroupsApproved
DescriptionA corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)
Structure
Thumb
Synonyms
Cordran
Fludrossicortide
Fludroxicortida
Fludroxicortide
Fludroxycortid
Fludroxycortide
Fludroxycortidum
Flurandrenolide
Flurandrenolone
External Identifiers
  • Lilly 33379
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cordranointment.5 mg/gtopicalAqua Pharmaceuticals1965-10-18Not applicableUs
Cordrancream.5 mg/gtopicalAqua Pharmaceuticals1965-10-18Not applicableUs
Cordranlotion.5 mg/mLtopicalAqua Pharmaceuticals1963-03-19Not applicableUs
Cordrantape4 ug/cm2topicalActavis Pharma, Inc.1969-07-29Not applicableUs
Drenison Tape M 170 4mcg Sq Cmtape4 mcgtopicalEli Lilly Canada Inc1969-12-311999-08-11Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Flurandrenolidecream.5 mg/gtopicalTeligent Pharma, Inc.2016-04-13Not applicableUs
Flurandrenolide Creamcream.5 mg/gtopicalCintex Services, Llc2016-04-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Cordran SPWatson
DrenisonBiolab
HaelanTypharm Limited
Brand mixturesNot Available
SaltsNot Available
Categories
UNII8EUL29XUQT
CAS number1524-88-5
WeightAverage: 436.5136
Monoisotopic: 436.226116993
Chemical FormulaC24H33FO6
InChI KeyInChIKey=POPFMWWJOGLOIF-XWCQMRHXSA-N
InChI
InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-17-en-16-one
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)CC[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Meta-dioxolane
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions
PharmacodynamicsFlurandrenolide is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions.
Mechanism of actionFlurandrenolide is a topical corticosteroid. It is normally applied to a plastic tape called Cordran. Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions. Flurandrenolide, which is slowly released from the Cordran tape, binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.
Related Articles
AbsorptionOnce absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to those of systemically administered corticosteroids
Volume of distributionNot Available
Protein bindingCorticosteroids are bound to plasma proteins in varying degrees.
Metabolism

Primarily hepatic

Route of eliminationTopical corticosteroids can be absorbed from normal intact skin. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half lifeNot Available
ClearanceNot Available
ToxicitySystemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9796
Blood Brain Barrier+0.9739
Caco-2 permeable+0.5279
P-glycoprotein substrateSubstrate0.8046
P-glycoprotein inhibitor INon-inhibitor0.6488
P-glycoprotein inhibitor IINon-inhibitor0.7127
Renal organic cation transporterNon-inhibitor0.7839
CYP450 2C9 substrateNon-substrate0.862
CYP450 2D6 substrateNon-substrate0.8911
CYP450 3A4 substrateSubstrate0.7258
CYP450 1A2 substrateNon-inhibitor0.9294
CYP450 2C9 inhibitorNon-inhibitor0.9269
CYP450 2D6 inhibitorNon-inhibitor0.9481
CYP450 2C19 inhibitorNon-inhibitor0.9398
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9098
Ames testNon AMES toxic0.8398
CarcinogenicityNon-carcinogens0.934
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.2002 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9652
hERG inhibition (predictor II)Non-inhibitor0.5679
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Watson pharmaceuticals inc
  • Watson laboratories inc
  • Alpharma us pharmaceuticals division
Packagers
Dosage forms
FormRouteStrength
Creamtopical.5 mg/g
Lotiontopical.5 mg/mL
Ointmenttopical.5 mg/g
Tapetopical4 ug/cm2
Tapetopical4 mcg
Prices
Unit descriptionCostUnit
Cordran (80 X 3 Inch) Box Box105.02USD box
Cordran 4 mcg/sqcm Tape (24 X 3 Inch) Box53.63USD box
Cordran 0.05% lotion4.8USD ml
Cordran sp 0.05% cream4.8USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point251 °CPhysProp
water solubilityInsolubleNot Available
logP0.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0578 mg/mLALOGPS
logP2.02ALOGPS
logP1.56ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.73ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity110.79 m3·mol-1ChemAxon
Polarizability45.74 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Casas-Campillo, C.; U.S. Patent 3,119,748; January 28, 1964; assigned to Syntex Corporation, Panama.
Ringold, H.J., Zderic, J.A., Djerassi, C. and Bowers, A.; U.S. Patent 3,126,375; March 24, 1964; assigned to Syntex Corporation, Panama.

General ReferencesNot Available
External Links
ATC CodesD07AC07D07CC03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flurandrenolide.
AldesleukinFlurandrenolide may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Flurandrenolide can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Flurandrenolide can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flurandrenolide.
AmiodaroneThe serum concentration of Flurandrenolide can be increased when it is combined with Amiodarone.
Amphotericin BFlurandrenolide may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Flurandrenolide can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Flurandrenolide can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Flurandrenolide.
BazedoxifeneThe serum concentration of Flurandrenolide can be increased when it is combined with Bazedoxifene.
BendroflumethiazideFlurandrenolide may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Flurandrenolide.
Bismuth SubcitrateThe bioavailability of Flurandrenolide can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Flurandrenolide can be increased when it is combined with Boceprevir.
BumetanideFlurandrenolide may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flurandrenolide.
Calcium carbonateThe bioavailability of Flurandrenolide can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Flurandrenolide can be decreased when it is combined with Carbamazepine.
CeritinibFlurandrenolide may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Flurandrenolide can be increased when it is combined with Ceritinib.
ChlorothiazideFlurandrenolide may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Flurandrenolide can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneFlurandrenolide may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Flurandrenolide can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Flurandrenolide can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Flurandrenolide can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flurandrenolide.
CoumaphosThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Coumaphos.
DarunavirThe serum concentration of Flurandrenolide can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Dichlorvos.
DienestrolThe serum concentration of Flurandrenolide can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Flurandrenolide can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flurandrenolide.
DihydrotestosteroneFlurandrenolide may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Edrophonium.
EnzalutamideThe serum concentration of Flurandrenolide can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Flurandrenolide can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Flurandrenolide can be increased when it is combined with Estriol.
EstroneThe serum concentration of Flurandrenolide can be increased when it is combined with Estrone.
Etacrynic acidFlurandrenolide may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Flurandrenolide can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Fenthion.
FluoxymesteroneFlurandrenolide may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Flurandrenolide can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Flurandrenolide can be decreased when it is combined with Fosphenytoin.
FurosemideFlurandrenolide may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Flurandrenolide can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Flurandrenolide.
HexestrolThe serum concentration of Flurandrenolide can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flurandrenolide.
HydrochlorothiazideFlurandrenolide may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideFlurandrenolide may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Flurandrenolide can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Flurandrenolide.
IndapamideFlurandrenolide may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Flurandrenolide can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Flurandrenolide.
ItraconazoleThe serum concentration of Flurandrenolide can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Flurandrenolide can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Flurandrenolide can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Flurandrenolide can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flurandrenolide.
MestranolThe serum concentration of Flurandrenolide can be increased when it is combined with Mestranol.
MethyclothiazideFlurandrenolide may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneFlurandrenolide may increase the fluid retaining activities of Methyltestosterone.
MetolazoneFlurandrenolide may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Flurandrenolide can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Minaprine.
MitotaneThe serum concentration of Flurandrenolide can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Flurandrenolide.
NefazodoneThe serum concentration of Flurandrenolide can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Flurandrenolide can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Neostigmine.
NevirapineThe serum concentration of Flurandrenolide can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Nicorandil.
OxandroloneFlurandrenolide may increase the fluid retaining activities of Oxandrolone.
OxymetholoneFlurandrenolide may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Flurandrenolide can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Flurandrenolide can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Flurandrenolide.
PhenytoinThe serum concentration of Flurandrenolide can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Physostigmine.
PiretanideFlurandrenolide may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Flurandrenolide can be increased when it is combined with Polyestradiol phosphate.
PolythiazideFlurandrenolide may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Flurandrenolide can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Flurandrenolide can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pyridostigmine.
QuinestrolThe serum concentration of Flurandrenolide can be increased when it is combined with Quinestrol.
QuinethazoneFlurandrenolide may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Flurandrenolide.
RifabutinThe serum concentration of Flurandrenolide can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Flurandrenolide can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Flurandrenolide can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Flurandrenolide can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flurandrenolide.
SaquinavirThe serum concentration of Flurandrenolide can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Flurandrenolide.
StanozololFlurandrenolide may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Flurandrenolide can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Flurandrenolide can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Flurandrenolide.
TelaprevirThe serum concentration of Flurandrenolide can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Flurandrenolide can be increased when it is combined with Telithromycin.
TestosteroneFlurandrenolide may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Flurandrenolide can be increased when it is combined with Tibolone.
TorasemideFlurandrenolide may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Trichlorfon.
TrichlormethiazideFlurandrenolide may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Tubocurarine.
VoriconazoleThe serum concentration of Flurandrenolide can be increased when it is combined with Voriconazole.
WarfarinFlurandrenolide may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Flurandrenolide can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Baschant U, Tuckermann J: The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010 May 31;120(2-3):69-75. doi: 10.1016/j.jsbmb.2010.03.058. Epub 2010 Mar 24. [PubMed:20346397 ]
  2. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28. [PubMed:16255837 ]
  3. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Emptoz-Bonneton A, Cousin P, Seguchi K, Avvakumov GV, Bully C, Hammond GL, Pugeat M: Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. [PubMed:10634411 ]
  4. Smith CL, Power SG, Hammond GL: A Leu----His substitution at residue 93 in human corticosteroid binding globulin results in reduced affinity for cortisol. J Steroid Biochem Mol Biol. 1992 Aug;42(7):671-6. [PubMed:1504007 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23